Enlivex Therapeutics Ltd. received approval from the Danish Medicines Agency to enroll patients in its Phase 2b study of Allocetra for moderate‑to‑severe age‑related primary knee osteoarthritis. The clearance follows the company’s recent FDA approval to launch the same trial in the United States and expands the program to include sites in Denmark and Poland, creating a global, multicenter, randomized, double‑blind, placebo‑controlled study.
The Danish approval is a key regulatory milestone that enables Enlivex to gather robust clinical data across three countries. It demonstrates continued support for the company’s immunotherapy platform and positions Allocetra closer to potential market approval, reinforcing the company’s strategy to deliver a disease‑modifying therapy in a market that currently has no approved disease‑modifying options.
Enlivex operates a dual business model that combines longevity therapeutics with a prediction‑markets treasury strategy. The company reported a net income of $1.23 billion for 2025, largely driven by appreciation of treasury and RAIN token assets rather than core operating revenue. The trial expansion does not alter that financial picture but underscores the company’s commitment to clinical progress and its ability to fund the expanded program.
Management emphasized the significance of the Danish approval. CEO Oren Hershkovitz said, "Following the recent FDA clearance, the approval in Denmark marks another key step in executing our global Phase 2b strategy for Allocetra™. Expanding into Europe reflects our commitment to advancing a unified, multinational development program designed to generate robust clinical data." He added that enrollment will begin in Q2 2026 with an expected 150 patients.
The trial will enroll moderate‑to‑severe age‑related primary knee osteoarthritis patients in a randomized, double‑blind, placebo‑controlled design. The global program aims to evaluate pain reduction, functional improvement, and quality‑of‑life benefits, providing data that could support a disease‑modifying indication in a market with over 32 million affected Americans and projected 78 million by 2040.
Analysts note that while the regulatory approval is a positive development, Enlivex’s financial results are heavily influenced by treasury gains, and the company’s operational profitability remains modest. The company’s current liquidity remains strong with a current ratio of 6.43, giving it capacity to fund the expanded trial.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.